RxDoctor Payments Data

Ann Habenicht, DO

Neuromusculoskeletal Medicine & OMM · Beavercreek, OHNPI 1497701890

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Collegium Pharmaceutical, Inc. accounts for 68.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $235 and has fallen 60.2% since, to $94 in 2024.

$560in general payments, 2019–2025

Across 44 payments — averaging $12.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$383
  • Biodelivery Sciences International, Inc.$113
  • Vertiflex, Inc.$28
  • Pfizer$26
  • Takeda Pharmaceuticals U.S.A., Inc.$10

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few neuromusculoskeletal medicine & omm providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$59,221
Medicare patients
92
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl21$18,630
Buprenorphine12$5,757
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen156$4,021
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen107$2,724
Oxycodone Hcl67$1,807
Gabapentin73$923
Pregabalin45$871
Tizanidine Hcl37$226
Tramadol Hcl28$144
Cyclobenzaprine Hcl24$139
Baclofen15$102
Zolpidem Tartrate26$84
Lorazepam11$62
Naproxen13$39
Meloxicam22$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$383$18,63021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine & omm providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other neuromusculoskeletal medicine & omm in Beavercreek

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →